Advertisement

Picture [iito] Made Without Love 650x80px
Document › Details

Elicera Therapeutics AB. (4/27/21). "Press Release: Elicera Therapeutics Files a Patent Application for the Development of the Next Generation Oncolytic Viruses". Gothenburg.

Organisations Organisation Elicera Therapeutics AB
  Organisation 2 University of Uppsala (Uppsala University)
Products Product ELC-201 oncolytic virus (Elicera Therapeutics)
  Product 2 ELC-100 (AdVince) (Elicera Therapeutics)
Person Person El-Mosleh, Jamal (Elicera Therapeutics 202010– CEO before Immunicum AB 200709– CEO)
     


Elicera Therapeutics, a clinical phase cell and gene therapy company that develops immunooncological treatments focusing on CAR T cells and oncolytic viruses, announced today that the company has filed a patent application to protect the development of its drug candidate ELC- 201, a next generation of oncolytic virus.

ELC-201 is the second oncolytic virus in Elicera Therapeutic's product portfolio. It is based on an adenovirus that has been genetically modified in a way that makes the treatment applicable to most cancers and the patent application protects the application of two more genetic modifications in combination that together give the drug candidate three mechanisms of action.

In addition to ELC-201, Elicera is also developing ELC-100, an oncolytic virus developed for the treatment of neuroendocrine tumors. ELC-100 is currently in an ongoing Phase I / II clinical trial.


Contacts:

Jamal El-Mosleh, CEO
Tel: +46703319051
jamal.elmosleh@elicera.com


About Elicera Therapeutics

Elicera is a clinical stage cell and gene therapy company active in the field of immuno-oncology. Based on the leading research by Professor Magnus Essand’s work at Uppsala University, the Company has four drug candidates, two in the field of CAR-T cells and two in the field of oncolytic viruses. Most advanced is ELC-100, an oncolytic virus for NET which is Phase I/II, while ELC-301, an enhanced CAR-T therapy is due to enter Phase I second half of 2022. Elicera has also completed development of a proprietary technology platform called iTANK (immunoTherapies Activated with NAP for efficient Killing) for optimization of any CAR T-cell therapy under development and generation of a second mode of action through activation of CD8+ T-cells against cancer.

For more information, please visit www.elicera.com

   
Record changed: 2021-05-21

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Elicera Therapeutics AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top